Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 31;7(4):100530. doi: 10.1016/j.esmoop.2022.100530

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

STAT3 and macrophage polarization biomarker analysis of paired pre-/on-treatment biopsies from matched metastatic lesions of 11 patients. (A) Representative images of biopsies with IHC staining for phosphorylated STAT3 (black arrows: pSTAT3+ nuclei). (B) pSTAT3+ nuclei frequencies in pre-/on-treatment samples for each patient (log-scale). (C) Percentage change in the frequency of pSTAT3+ nuclei normalized to the pre-treatment frequency for all patients, ordered by change. (D) Measured M1(MHCII+/CD68+):M2(CD163 or CD206) ratio in pre-/on-treatment samples for each patient (log-scale). (E) Fold change in the M1:M2 ratio between pre- and on-treatment biopsies for all patients. (F) M1:M2 ratio fold change between pre- and on-treatment samples for samples stratified on the basis of an observed pSTAT3+ nuclei decrease.

^∗Archival/on-treatment pair.

^†Pre-/on-treatment pair from non-matched metastatic lesions.